The Department of Pharmaceuticals (DoP), in collaboration with Federation of Indian Chambers of Commerce & Industry (FICCI) and Indian Pharmaceutical Alliance, will host the 9th edition of India Pharma 2026 on April 13–14, 2026, at Federation House, New Delhi.

The event will be held under the theme “Discover in India: Leapfrogging life-sciences innovation,” reflecting the country’s ambition to emerge as a global hub for pharmaceutical innovation. The focus will be on advancing life sciences to improve healthcare access, drive economic growth, and strengthen global health security.

India Pharma 2026 aims to accelerate the sector’s transition from a volume-driven model to a value- and innovation-led ecosystem. The platform will bring together global industry leaders, policymakers, researchers, and investors to promote collaboration across drug discovery, complex generics, and biosimilars.

Key highlights of the event include a CEO roundtable with participation from the Ministry of Chemicals and Fertilisers, discussions on policy frameworks to catalyse innovation, unlocking CRDMO potential, strengthening regulatory ecosystems, enabling pharma financing, and leveraging AI and emerging technologies for disruptive innovation.

The event is expected to attract a wide range of stakeholders, including policymakers, regulators, public health officials, pharmaceutical manufacturers, academia, research institutions, think tanks, and investors.

India continues to strengthen its position as the “Pharmacy of the World,” being the third-largest pharmaceutical producer globally by volume. The country’s pharmaceutical exports reached USD 27.85 billion in FY24, registering a growth of 9.66 Percent, and account for nearly 9.67 Percent of total merchandise exports.

The domestic pharmaceutical market is projected to grow to USD 65 billion by 2024 and further to USD 130 billion by 2030. India is also a global leader in generics, supplying around 20 Percent of the world’s demand and manufacturing approximately 60,000 generic brands across 60 therapeutic categories.

Additionally, India contributes about 60 Percent of global vaccine production and meets a significant share of the World Health Organization (WHO) demand for key vaccines such as DPT, BCG, and measles.

With over 500 API manufacturers contributing around 8 Percent to the global API market, the sector is poised for sustained growth in the post-pandemic era, driven by innovation, quality manufacturing, and increasing global demand for affordable healthcare solutions.